Biotech under pressure, Valeant plunges 10%

30 Ottobre 2015, di Redazione Wall Street Italia

Valeant’s “astronomical” price increases take center stage and Pfizer gets dragged in. Having put all its peers to shame in terms of price hikes, VRX shareholders appear anxious that the ‘no-brainer’ may just become the example to be made of by an anxious-to-show-some-action Congress.